ProfileGDS4814 / ILMN_2374234
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 73% 74% 70% 73% 74% 73% 72% 72% 72% 74% 74% 71% 73% 73% 70% 71% 73% 72% 72% 72% 70% 71% 73% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)84.493673
GSM780708Untreated after 4 days (C2_1)89.489874
GSM780709Untreated after 4 days (C3_1)74.162470
GSM780719Untreated after 4 days (C1_2)84.265673
GSM780720Untreated after 4 days (C2_2)92.452274
GSM780721Untreated after 4 days (C3_2)84.726773
GSM780710Trastuzumab treated after 4 days (T1_1)82.46172
GSM780711Trastuzumab treated after 4 days (T2_1)81.705172
GSM780712Trastuzumab treated after 4 days (T3_1)83.567572
GSM780722Trastuzumab treated after 4 days (T1_2)91.192274
GSM780723Trastuzumab treated after 4 days (T2_2)94.695874
GSM780724Trastuzumab treated after 4 days (T3_2)76.899271
GSM780713Pertuzumab treated after 4 days (P1_1)86.135773
GSM780714Pertuzumab treated after 4 days (P2_1)84.68273
GSM780715Pertuzumab treated after 4 days (P3_1)74.883670
GSM780725Pertuzumab treated after 4 days (P1_2)78.720871
GSM780726Pertuzumab treated after 4 days (P2_2)85.370873
GSM780727Pertuzumab treated after 4 days (P3_2)81.86172
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)80.796172
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)83.235872
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)71.732470
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)79.162771
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)87.674273